


iHealthcare

Group Holdings Ltd

**UNREVIEWED
CONDENSED
CONSOLIDATED
INTERIM RESULTS**
for the six months ended
31 August 2022





*Calculated using the equity attributable to the Owners of the Company.

Introduction

The Board of Directors is pleased to present the unreviewed condensed consolidated financial statements for the six months ended 31 August 2022.

Overview

iHealthcare Group Holdings Limited (“**iHealthcare Holdings**”) has shown great resilience in recovering and normalising operational activities post the Covid-19 pandemic. Although the overall economy is still recovering from the impact of the pandemic coupled with other factors such as the increase in the official prime rate, the volatility of the South African Rand and global supply challenges, the Group was in a financial position to pay a dividend to its shareholders during the reporting period.

The pro-active measures implemented by iHealthcare Holdings’ management resulted in iHealthcare Holdings and its subsidiaries (collectively referred to as the “**Group**” and individually referred to as “**Group entities**”) improving its financial position and management continues to take action to ensure the Group remains both financially and operationally healthy.

Segment Performance

Ophthalmology

The segment increased revenue by 13.1% and with an operating profit before tax amounting to R 2 720 714 (Aug 2021: R 4 485 563). The entities in this cluster operated at normalised operational levels compared to prior reporting periods as the South African Government lifted South Africa’s national state of disaster on 5 April 2022.

Since the global easing of COVID-19 related restrictions, the Group attended various exhibitions and conferences to showcase its products. Furthermore, the Group capitalised additional demo equipment. The increase in conference expenses and depreciation of demo equipment contributed to the decrease in the operating profit before tax of the segment.

Financial Results

Statement of profit or loss

As a result of the normalised operating levels of the Group since the lifting of the national state of disaster, revenue for the reporting period increased by 13.1% to R 23 603 715 (Aug 2021: R 20 853 534).

Although the South African Rand was impacted by global economic instabilities, the Group managed to limit the exposure to these fluctuations resulting in a foreign exchange loss recognised in profit or loss amounting to R 66 709 (Aug 2021: R 73 466 gain).

The increase in conference expenses, short-term employee benefits and depreciation of demo equipment contributed to the decrease in the operating profit before tax of the Group.

The average weighted number of shares, from which earnings per share and headline earnings per share are derived, was 2 471 462 (Aug 2021: 1 547 278) shares at the interim reporting date. The increase in number of shares relates to the issue of additional shares in respect of the scheme of arrangement as disclosed in the audited consolidated financial statements for the reporting period ended 28 February 2022.

Basic earnings per share decreased by 41.1% to 79.1 cents per share (cps) (Aug 2021: 134.3 cps) and headline earnings per share decreased by 41.1% to 79.1 cents per share (cps) (Aug 2021: 134.4 cps).

Statement of financial position

The working capital* of the Group decreased to R 10 527 556 (Aug 2021: R 16 171 900). The decrease is as a direct result of an increased trade creditors balance due to the renegotiated payment terms with a major supplier. The Group continued to recover significant customer balances within the terms provided to these customers.

**The working capital includes inventories, trade and other receivables and trade and other payables.*

Based on the overall inputs into the valuation of the cash-settled share-based payment scheme and the overall Group performance for the interim period, no adjustment to the fair value of the cash-settled share-based payment liability was recognised in profit or loss.

Statement of cash flows

Cash generated from operations increased to R 5 441 922 (Aug 2021: R 4 091 281) due to the overall increase in operational levels of the active subsidiaries of the Group in conjunction with the decrease in the working capital of the Group resulting in an inflow related to working capital amounting to R 1 729 679 (Aug 2021: R 2 099 420 outflow).

The Group acquired additional plant and equipment amounting to R 222 343 (Aug 2021: R 766 822). The overall cash and cash equivalents balance of the Group increased by R 1 567 463 (Aug 2021: R 2 280 329) after the payment of a dividend to ordinary shareholders amounting to R 3 000 000 (Aug 2021: R nil) during the reporting period.

Governance

Sound corporate governance is inherent in iHealthcare Holdings' values, culture, processes, functions and organisational structure. The Board is fully committed to the highest standard of governance and accountability and delivery of the outcomes of an ethical culture, good performance, effective control and legitimacy.

Composition of the Board

There have been changes to the Board of Directors during the interim reporting period. These changes can be summarised as follows:

Director Name	Description of Change	Appointment date	Resignation date
Dr B Khantsi [^]	Appointed as an independent non-executive director	1 Sept 2022*	N/A
Dr A Jacobsz [^]	Resigned during the period	N/A	7 Apr 2022

[^]Independent non-executive director.

*Appointed to the Board after the reporting period.

After taking all changes into account, the Board comprises 7 (seven) directors, 1 (one) executive director and 6 (six) non-executive directors as at the publication of the interim results. The only executive director is the CEO.

Stakeholder engagement

Stakeholder relationships are built on the basis of open dialogue and mutual trust as sustainable value creation depends on successful engagement with stakeholders. These engagements assist iHealthcare Holdings to understand and respond to the interests and expectations of key stakeholders. The Group strives to ensure the completeness, timeliness, objectivity, reliability and consistency of information.

Dividends

The Company declared and paid a gross dividend amounting to R 3 000 000 during the six month reporting period ended 31 August 2022. No additional interim dividend is declared.

Prospects

The outlook for the year to 28 February 2023 remains uncertain. The industry is facing exchange rate volatility coupled with supply chain challenges, which could make it difficult to maintain earnings at the level of those recorded in the August 2022 reporting period.

For and on behalf of the Board



KJM Moja
Chairperson



D. P. Minsloo
CEO



JH Visser
CFO

30 November 2022
Pretoria

Consolidated statement of financial position

as at 31 August 2022

Figures in Rand	Group		
	As at 31 Aug 2022	As at 31 Aug 2021	Audited As at 28 Feb 2022
Assets			
Non-current assets			
Property, plant and equipment	5 216 865	3 996 511	5 753 912
Deferred tax	1 209 456	941 955	1 209 455
Total non-current assets	6 426 321	4 938 466	6 963 367
Current assets			
Inventories	13 327 396	12 494 644	10 476 774
Trade and other receivables	7 273 174	7 635 559	6 078 917
Current tax assets	-	7 328	-
Cash and cash equivalents	10 035 815	7 274 422	8 468 352
Total current assets	30 636 385	27 411 953	25 024 043
Total assets	37 062 706	32 350 419	31 987 410
Equity and liabilities			
Equity			
Stated capital	67 867 660	41 731 736	67 867 660
Retained losses	(42 296 174)	(24 802 286)	(41 251 825)
Total equity attributable to the owners of the Company	25 571 486	16 929 450	26 615 835
Non-controlling interests	-	9 532 358	-
Total equity	25 571 486	26 461 808	26 615 835
Liabilities			
Non-current liabilities			
Contract liabilities	-	652 050	588 525
Cash-settled share-based payment liability	1 112 196	674 304	1 112 196
Total non-current liabilities	1 112 196	1 326 354	1 700 721
Current liabilities			
Trade and other payables	10 073 014	3 958 303	3 454 345
Current tax liabilities	306 010	540 429	152 984
Contract liabilities	-	63 525	63 525
Total current liabilities	10 379 024	4 562 257	3 670 854
Total liabilities	11 491 220	5 888 611	5 371 575
Total equity and liabilities	37 062 706	32 350 419	31 987 410

Consolidated statement of profit or loss and other comprehensive income for the six months ended 31 August 2022

Figures in Rand	Notes	Group		
		Six months ended 31 Aug 2022	Six months ended 31 Aug 2021	Audited Twelve months ended 28 Feb 2022
Revenue	2	23 603 715	20 853 534	38 982 168
Cost of sales		(10 489 957)	(8 154 518)	(15 727 026)
Gross profit		13 113 758	12 699 016	23 255 142
Other income				
Gain on foreign exchange		-	73 466	-
Operating expenses		(10 352 996)	(8 301 554)	(18 362 438)
Impairment loss on trade receivables		(69 293)	(244 903)	(17 149)
Loss on disposal of property, plant and equipment		-	(3 053)	(3087)
Loss on foreign exchange		(66 709)	-	(83 231)
Employee benefit expense		(5 767 210)	(4 101 022)	(8 989 666)
Share-based payment expense		-	(674 304)	(1 112 196)
Administrative expenses		(1 231 184)	(1 166 963)	(2 255 982)
Other expenses		(3 218 570)	(2 111 309)	(5 901 127)
Operating profit before interest		2 760 792	4 470 928	4 892 704
Finance income		45 994	56 101	145 083
Finance costs		-	(26 708)	(26 708)
Profit before tax		2 806 786	4 500 321	5 011 079
Income tax expense		(851 135)	(1 319 747)	(1 676 478)
Profit for the period		1 955 651	3 180 574	3 334 601
Other comprehensive income		-	-	-
Total comprehensive income for the period		1 955 651	3 180 574	3 334 601
Total comprehensive income for the period attributable to:				
Owners of the Company		1 955 651	2 077 276	2 244 207
Non-controlling interests		-	1 103 298	1 090 394
		1 955 651	3 180 574	3 334 601
Earnings per ordinary share				
-Basic earnings per ordinary share (cents)	3	79.1	134.3	141.8
-Diluted earnings per ordinary share (cents)	3	79.1	134.3	141.8

Consolidated statement of changes in equity for the six months ended 31 August 2022

Figures in Rand	Group		
	Six months ended 31 Aug 2022	Six months ended 31 Aug 2021	Audited Twelve months ended 28 Feb 2022
Opening balance	26 615 835	23 281 234	23 281 234
Issue of ordinary shares	-	-	26 135 924
Issue of shares: non-controlling interests without a change in control	-	-	-
Total comprehensive income	1 955 651	3 180 574	3 334 601
Profit for the period	1 955 651	3 180 574	3 334 601
Other comprehensive income	-	-	-
Dividends paid to shareholders	(3 000 000)	-	-
Closing balance	25 571 486	26 461 808	26 615 835
Attributable to:			
Owners of the Company	25 571 486	16 929 450	26 615 835
Non-controlling interests	-	9 532 358	-
	25 571 486	26 461 808	26 615 835

Consolidated statement of cash flows

for the six months ended 31 August 2022

Figures in Rand	Group		
	Six months ended 31 Aug 2022	Six months ended 31 Aug 2021	Audited Twelve months ended 28 Feb 2022
Profit before tax	2 806 786	4 500 321	5 011 079
Adjusted for			
Finance income	(45 994)	(56 101)	(145 083)
Finance costs	-	26 708	26 708
Non-cash flow items			
Depreciation	882 158	797 513	1 385 785
Cash-settled share-based payment expense	-	674 304	1 112 196
Impairment loss (reversal) on trade receivables	69 293	244 903	17 149
Loss on disposal of property, plant and equipment	-	3 053	3 087
Changes in working capital	1 729 679	(2 099 420)	(1 841 634)
Cash generated from operations	5 441 922	4 091 281	5 569 287
Finance income received	45 994	56 101	145 083
Finance costs paid	-	(26 708)	(26 708)
Tax paid	(698 110)	(840 309)	(1 844 657)
Net cash from operating activities	4 789 806	3 280 365	3 843 005
Cash flows from investing activities			
Acquisition of property, plant and equipment	(222 343)	(766 822)	(136 510)
Proceeds from the disposal of property, plant and equipment	-	587	1 565
Repayments from loans receivable	-	112 409	112 409
Net cash used in investing activities	(222 343)	(653 826)	(22 536)
Cash flows from financing activities			
Repayments of lease liabilities	-	(346 210)	(346 210)
Dividends paid to shareholders	(3 000 000)		
Net cash used in financing activities	(3 000 000)	(346 210)	(346 210)
Net increase	1 567 463	2 280 329	3 474 259
Cash and equivalents at the beginning of the period	8 468 352	4 994 093	4 994 093
Cash and equivalents at the end of the period	10 035 815	7 274 422	8 468 352

Selected notes to the condensed consolidated interim financial statements for the six months ended 31 August 2022

continued

1. Salient features and of the condensed consolidated interim financial statements

The condensed consolidated interim financial statements comprise the condensed consolidated statement of financial position at 31 August 2022, the condensed consolidated statements of profit or loss and other comprehensive income, changes in equity and cash flows and notes for the period then ended.

Responsibility for interim results

The Board takes full responsibility for the preparation of the interim results including the condensed consolidated interim financial statements. The directors are also responsible for such internal control as the directors determine is necessary to enable the preparation of the condensed consolidated interim financial statements that are free from material misstatement, whether owing to fraud or error.

Reporting entity

iHealthcare Group Holdings Limited (the “iHealthcare Holdings” or the “Company”) is a company domiciled in South Africa. Its registration number is 2019/155531/06. The address of the Company’s registered office is Sappi Technology Centre, The Innovation Hub, Cnr Aaron Klug and Max Theiler Street, Persequor, Pretoria. The condensed consolidated interim financial statements of the Group as at and for the six months ended 31 August 2022 comprise the Company and its subsidiaries (collectively referred to as the “Group” and individually referred to as “Group entities”).

Basis of preparation and statement of compliance

The condensed consolidated interim financial statements for the six months ended 31 August 2022 have been prepared in accordance with the Group’s accounting policies under the supervision of the Chief Financial Officer, Mr JH Visser, CA(SA)(ANZ).

The condensed consolidated interim financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (“IFRS”), the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee, the Financial Reporting Pronouncements as issued by the Financial Reporting Standards Council, the Listings Requirements of the Cape Town Stock Exchange Proprietary Limited (*formerly 4 Africa Exchange Proprietary Limited*) (“CTSE”) and in the manner required by the Companies Act of South Africa, 2008 (Act 71 of 2008), as amended, and are based upon appropriate accounting policies consistently applied throughout the Group and supported by reasonable and prudent judgements and estimates.

The condensed consolidated interim financial results of the Group are prepared as a going concern on a historical basis.

The condensed consolidated interim financial results do not include all the information and disclosures required in the consolidated financial statements, and should be read in conjunction with the Group’s audited consolidated financial statements as at 28 February 2022.

Neither the condensed consolidated interim financial results as at and for the six months period ended 31 August 2021, nor this set of condensed consolidated interim financial results information and disclosure, have been reviewed or audited by the Company’s auditors, SizweNtsalubaGobodo Grant Thornton Incorporated. Any forward-looking statement has not been reviewed nor reported on by the Company’s external auditors.

Changes in accounting policies

The condensed consolidated interim financial statements do not include all the information and disclosures required in the audited consolidated financial statements, and should be read in conjunction with the Group’s audited consolidated financial statements as at 28 February 2022. The accounting policies adopted in the preparation of the condensed consolidated interim financial statements are consistent with those applied in the preparation of the Group’s audited consolidated financial statements for the reporting period ended 28 February 2022.

Use of estimates and judgements

The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements about carrying values of assets and liabilities that are not readily apparent from other sources.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis.

Changes to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Selected notes to the condensed consolidated interim financial statements for the six months ended 31 August 2022

continued

Salient features and of the condensed consolidated interim financial statements - *continued*

New and amended Standards and Interpretations issued but not yet effective

Management assessed all of the standards and interpretations and is of the opinion that none of these standards and interpretations will have a material impact on the results of the Group in future periods.

Functional and presentation currency

The condensed consolidated interim financial statements are presented in South African Rands, the functional currency of the Group. All amounts are rounded to the nearest thousand, except where another rounding measure has been indicated in the summarised condensed consolidated interim financial statements.

Comparative figures

Unless otherwise indicated, comparative figures refer six month reporting period ended 31 August 2021 and to the twelve month reporting period ended 28 February 2022.

Financial risk management

The Group's financial risk management objectives and policies are consistent with those disclosed in the audited consolidated financial statements as at and for the reporting period ended 28 February 2022.

Selected notes to the condensed consolidated interim financial statements for the six months ended 31 August 2022

continued

2. Revenue

	Group		
	31 Aug 2022 Rand	31 Aug 2021 Rand	Audited 28 Feb 2022 Rand
Revenue from contracts with customers	23 603 715	20 853 534	38 982 168
Total revenue	23 603 715	20 853 534	38 982 168

Disaggregation of revenue

In the following tables, revenue from contracts with customers is disaggregated by timing of revenue recognition, major service offering and geographical region. The tables also include a reconciliation of the disaggregated revenue with the Group's reportable segments.

	Group Ophthalmology segment		
	31 Aug 2021 Rand	31 Aug 2020 Rand	Audited 28 Feb 2021 Rand
Timing of revenue recognition			
At a point in time	23 412 165	20 853 534	38 918 643
Over a period of time	191 550	-	63 525
Total revenue	23 603 715	20 853 534	38 982 168
Major service offering			
Consumable product sales	22 887 165	20 853 534	38 918 643
Capital equipment sales	525 000	-	-
Services of equipment	191 550	-	63 525
Total revenue	23 603 715	20 853 534	38 982 168
Geographical region			
South Africa	23 603 715	20 853 534	38 979 348
Namibia	-	-	2 820
Total revenue	23 603 715	20 853 534	38 982 168

The remaining performance obligations in relation to the service element that have an expected duration of one year or less amounts to Rnil (Aug 2021: R63 525, Feb 2022: R63 525). The remaining performance obligations that have an expected duration of more than one year, in relation to the service element amounts to Rnil (Aug 2021: R127 050, Feb 2022: R63 525). The Group did not have any other remaining performance obligations at the current or prior reporting dates.

Selected notes to the condensed consolidated interim financial statements for the six months ended 31 August 2022

continued

3. Earnings and headline earnings per share

	Group		
	31 Aug 2022	31 Aug 2021	Audited 28 Feb 2022
Basic and diluted earnings per ordinary share			
Basic earnings per ordinary share has been calculated using the following:			
Profit for the period	1 955 651	3 180 574	3 334 601
Non-controlling interest	-	(1 103 298)	(1 090 394)
Earnings attributable to ordinary shareholders (Rand)	1 955 651	2 077 276	2 244 207
Weighted number of ordinary shares in issue	2 471 462	1 547 278	1 582 726
Weighted number of ordinary shares in issue for purposes of dilution	2 471 462	1 547 278	1 582 726
Basic earnings per ordinary shares (cents)	79.1	134.3	141.8
Diluted earnings per share (cents)	79.1	134.3	141.8
Headline and diluted headline earnings per ordinary share*			
Headline earnings per ordinary share has been calculated using the following:			
Earnings attributable to ordinary shareholders	1 955 651	2 077 276	2 244 207
Loss on disposal of property, plant and equipment net of tax	-	2 198	2 223
Headline earnings for the period (Rand)	1 955 651	2 079 474	2 246 430
Weighted number of ordinary shares in issue	2 471 462	1 547 278	1 582 726
Weighted number of ordinary shares in issue for purposes of dilution	2 471 462	1 547 278	1 582 726
Headline earnings per ordinary shares (cents)	79.1	134.4	141.9
Diluted headline earnings per share (cents)	79.1	134.4	141.9

*Although headline earnings is not required by the CTSE Listing Requirements this represents a measure reviewed by management and is based on the requirements of the SAICA Circular 1/2019.

Reconciliation of weighted average number of shares in issue

	Group		
	31 Aug 2022	31 Aug 2021	Audited 28 Feb 2022
Number of shares			
Shares in issue at the beginning of the period	2 471 462	1 547 278	1 547 278
Shares issued (weighted)	-	-	35 448
	2 471 462	1 547 278	1 582 726
Dilutionary effect of LTI scheme	-	-	-
Weighted number of ordinary shares in issue - dilution	2 471 462	1 547 278	1 582 726

Selected notes to the condensed consolidated interim financial statements

for the six months ended 31 August 2022

continued

4. Segment analysis

The Group has the following two business units as strategic divisions, which are reportable segments. These divisions offer different products and services, and are managed separately because they require different strategies.

The segments of the Group are based on the information reported to the chief operating decision-maker (Chief Executive Officer) and have not changed from the prior reporting period. The Group primarily operates in South Africa.

All inter-segment transactions are priced on an arm's length basis.

Reportable segments	Operations
Ophthalmology	The ophthalmology segment provides a service offering specialising within the ophthalmology medical field to hospitals, pharmacies and medical practitioners. The service offering includes the sale of consumables, equipment and pharmaceutical products to customers in South Africa and Namibia.
Group services	Group Central Services provides strategic direction and shared services to the Group.

Business unit	Group		
	31 Aug 2022	31 Aug 2021	Audited 28 Feb 2022
External revenue analysis			
Ophthalmology	23 603 715	20 853 534	38 982 168
	23 603 705	20 853 534	38 982 168
Profit after tax analysis			
Operating profit before tax	2 806 786	4 500 321	5 011 079
Ophthalmology	2 720 714	4 485 563	4 967 723
Group services	86 072	14 758	43 356
Income tax expense	(851 135)	(1 319 747)	(1 676 478)
Ophthalmology	(816 706)	(1 309 690)	(1 639 863)
Group services	(34 429)	(10 057)	(36 615)
Profit for the period	1 955 651	3 180 574	3 334 601
Ophthalmology	1 904 008	3 175 873	3 327 860
Group services	51 643	4 701	6 741
The following items are included in the profit/(loss) before tax:			
Depreciation	(882 158)	(797 513)	(1 385 785)
Ophthalmology	(876 081)	(797 513)	(1 385 785)
Group services	(6 077)	-	-
Finance income	45 994	56 101	145 083
Ophthalmology	45 994	56 101	145 083
Group services	-	-	-
Finance costs	-	(26 708)	(26 708)
Ophthalmology	-	(26 708)	(26 708)
Group services	-	-	-

Selected notes to the condensed consolidated interim financial statements for the six months ended 31 August 2022

continued

Segment analysis - continued

Business unit	Group		Audited
	31 Aug 2022	31 Aug 2021	28 Feb 2022
Net operating assets analysis			
Ophthalmology	(41 124 780)	(14 044 851)	(40 028 788)
Group services*	66 696 266	40 506 659	66 644 623
	25 571 486	26 461 808	26 615 835

*The net operating assets analysis is performed prior to the elimination of intergroup transactions and balances.

5. COVID-19 global pandemic

Widespread local and global uncertainty associated with the COVID-19 pandemic was, and remains, prevalent after the reporting date. On 1 May 2020 a risk-adjusted phased-in approach of economic activity was implemented and promulgated in terms of the Disaster Management Act of South Africa, 2002 (Act 57 of 2002). This risk-adjusted phased-in approach continued albeit the levels of economic activity were adjusted according to the various levels instituted by the South African government throughout the reporting period.

During the reporting period, on 05 April 2022, the South African government has lifted South Africa's national state of disaster.

It is important to note that the material operating entity of the Group, namely IsoClear Proprietary Limited ("IsoClear") was classified as an essential service provider during the entire reporting period. Operations were less restricted during the risk-adjusted phased-in approach and the previous delays in the execution of elective medical procedures normalised during the period resulting in a normalised operational level during the six months ended 31 August 2022.

Going forward, the extent of the impact of COVID-19 remains uncertain and cannot be predicted. The financial position and operating results of the Group may, to a certain extent, depend on future developments.

6. Going concern

Following due consideration of the operating budgets, an assessment of Group debt covenants and funding requirements, solvency and liquidity, the key risks, outstanding legal, insurance and taxation issues, the impact of the COVID-19 pandemic and other pertinent matters presented by management, as and when applicable, the Board has recorded that it has reasonable expectations that the Group has adequate resources and the ability to continue in operations for the foreseeable future. For these reasons, the condensed consolidated interim financial statements have been prepared on the going concern basis.

However, as discussed the extent of the impact of the COVID-19 pandemic remains uncertain and cannot be predicted by the Board.

7. Events after the reporting date

Other than as disclosed below, there were no events material to the understanding of the financial statements that occurred after the reporting date and the authorisation date of the financial statements.

Appointment of director

Dr B Khantsi was appointed to the Board effective 1 September 2022.

Specific repurchase of shares

After the reporting date, the Company repurchased 22 550 shares under the specific authority granted by shareholders at the AGM held on 29 September 2022. These shares was cancelled and delisted from the CTSE.

iHealthcare Group Holdings Limited

Incorporated in the Republic of South Africa
Company registration number: 2019/155531/06
("iHealthcare" or "the Company" or "the Group")
Share code: 4AIHGH
ISIN: ZAE400000077

Directors

Dr B Khantsi^
AP Coetzee^
Dr TB Maleka^
KJM Moja (Chairperson)^
Dr PJJ Odendaal
Dr FJ Potgieter^
D Prinsloo (Chief Executive Officer)

^Independent non-executive.

Business address

Sappi Technology Centre
The Innovation Hub
Cnr Aaron Klug and Max Theiler Street
Persequor
Pretoria
0020

Company Secretary

FluidRock Co Sec Proprietary Limited

Unit 5
Berkley Office Park
8 Bauhinia Street
Highveld Techno Park
Centurion
0169

External Issuer Agent

Pallidus Exchange Services Proprietary Limited

Die Groenhuis
38 Garsfontein Road
Waterkloof
Pretoria
0145

Transfer Securities

CTSE Registry Services Proprietary Limited

5th Floor
68 Albert Road
Woodstock
Cape Town
7925

Auditors

SizweNtsalubaGobodo Grant Thornton Incorporated

Summit Place Office Park
Building 4
221 Garsfontein Road
Menlyn
0081

iHealthcare
Group Holdings Ltd

www.ihgh.co.za